Dr. Greg Martin Parts With BU BME
As of the end of January, Dr. Greg Martin has moved on from Boston University Biomedical Engineering to continue serving his discipline in the medical devices field. Dr. Greg Martin served as the Director of the Coulter Translational Research Partnership Program in the BME department from November 2013 until January 2017 with the goal of enhancing clinical impact and wealth creation via the transfer of innovative intellectual properties from University laboratories to commercial practice. Greg helped BME Faculty identify technologies with promising commercial potential and pair them with clinical research partners. One of those BME faculty members is Dr. Jonathan Rosen, with whom he helped run two successful graduate level courses and one senior level requirement course this past fall. He worked with the BU Office of Technology development to conduct technical and market review and perform regulatory pathway and intellectual property strategy analysis.
He oversaw the $1,000,000 in annual funding from the Coulter Foundation and University cost share to fund this effort. Two notable translation successes are Professor Damiano’s artificial pancreas effort, originally funded as a Coulter project from 2006-2008, was spun out of BU as Beta Bionics with a $5,000,000 equity investment from Ely Lilly. The second recent translation is that of Constant Therapy, which was funded as a Coulter project in 2012-2013 and spun out of BU in 2014 with a $750,000 angel investment. They recently raised $2,000,000 in equity financing.
Greg will be moving on in a role that he is used to joining a Harvard-Wyss spinout, called Opsonix. They are developing a device to treat patients who have sepsis.
Greg’s past experience was as an executive, entrepreneur, engineer and scientist with 25 years’ experience taking medical technologies from concept to bedside to commercialization in academic, start-up and corporate environments. He has a track record of success in executive management, team building, change/crisis management, business development, product launch, marketing, operations, product development, R&D, manufacturing, clinical research, and regulatory affairs.
He previously was the Vice President of Research and Development at Hologic, a publicly-traded medical device company focused on women’s health. Prior to Hologic, he was the Chief Technology Officer and co-founder of Hemedex which developed a bedside cerebral blood flow monitor that was distributed by the Codman Division of Johnson & Johnson. Before that, he was a Research Scientist in the Harvard-MIT Division of Health Sciences and Technology at MIT. Dr. Martin received his BS, MS and PhD degrees in Mechanical Engineering from MIT. He has 8 issued US patents and 12 peer-reviewed publications.
Dr. Martin will be thoroughly missed and we wish him the best in his new adventures!
View all posts